Zemprocitinib

泽普昔替尼

Report date: 2026/05/06 20:02:28
NME

Base Information

Drug NameZemprocitinib
Drug Alias NameLNK-01001LNK01001LNK-001LNK001LNK-207 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK1 inhibitors
TargetsTyrosine-protein kinase JAK1
Therapy Area/IndicationsDermatitis, AtopicArthritis, RheumatoidSpondylitis, Ankylosing +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesLynk Pharmaceutical (Hangzhou) Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer CenterLynk Pharmaceutical (Hangzhou) Co LtdNanjing Simcere Dongyuan Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsDermatitis, AtopicArthritis, RheumatoidSpondylitis, Ankylosing +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A